ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX 6.38
+0.38 (6.33%)
At close: Dec 5, 2025
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
32.07M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
ImmuPharma News
- 11 days ago - FTSE Flat as Wall Street Gains Fail to Inspire - Investomania
- 12 days ago - AIM Market Roundup: Trellus Health, Great Western Mining, EMV Capital - The Armchair Trader
- 3 months ago - AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise - The Armchair Trader
- 3 months ago - AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals - The Armchair Trader
- 3 months ago - AIM Market Roundup: ImmuPharma, N4 Pharma, Versarien - The Armchair Trader
- 4 months ago - AIM Market Roundup: Catenai, Europa Oil & Gas, Faron Pharma - The Armchair Trader
- 4 months ago - FTSE Rises as Investors Eye Tariff Deadline - Investomania
- 9 months ago - FX positioning info - Net speculative EUR longs surged in a sharp rise from previous week - Forexlive